Skip to main content
Premium Trial:

Request an Annual Quote

Verisante Begins FDA Submission Process for Aura Device

Premium

NEW YORK (GenomeWeb News) – Verisante Technology said this week that it has begun submitting an application to the US Food and Drug Administration for 510(k) clearance of its Aura skin cancer detection device.

"Verisante has now submitted documents to the FDA as we begin the formal application process for approval to market and sell Aura in the US," CEO Thomas Braun said in a statement.

The Aura uses Raman spectroscopy to measure the levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions to distinguish between benign and malignant lesions. By comparing the patterns of spectra generated by the device, clinicians can differentiate between the two.

The company has received for the device Health Canada approval, Australian Department of Health approval, and an EU CE mark for the device. It is also pursuing regulatory approval in Brazil and Mexico.

Verisante launched sales of the Aura in February 2013, placing an initial production run of 10 devices in Canada and Europe.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.